C50.929 Insurance Policy Changes

ICD-10 C50.929 is officially defined as "Malignant neoplasm of unspecified site of unspecified male breast." code C50.929 is referenced in 27 tracked payer policy changes from Healthfirst, Excellus BlueCross BlueShield, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C50.929 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Healthfirst · Effective Apr 1, 2026High impact
NYS Medicaid Breast Cancer Selective Program Reimbursement Policy
Healthfirst's NYS Medicaid Breast Cancer Selective Program policy (PO-RE-168v1) requires prior authorization for all breast cancer surgical procedures under the program, and those procedures must be performed at NYS-approved facilities. Services rendered at restricted facilities are not eligible for reimbursement, and authorization requests listing a restricted facility will be denied. The policy applies only when a qualifying diagnosis code from Appendix A is linked to a qualifying procedure code, and Appendix A states the Medicaid breast cancer service exclusion is effective April 1, 2025.
Excellus BlueCross BlueShield · Effective Apr 16, 2026Medium impact
Germline Genetic Testing for Hereditary Cancers 2.02.60
Excellus BlueCross BlueShield policy 2.02.60 considers germline genetic testing for hereditary cancer medically appropriate in listed circumstances, including when a blood relative has a known pathogenic or likely pathogenic variant, when a pathogenic or likely pathogenic variant is found on tumor genomic testing, when results aid systemic therapy or surgical decisions, and when individuals meet specific criteria for breast, ovarian, pancreatic, prostate, colorectal, Cowden syndrome, Li-Fraumeni syndrome, hereditary diffuse gastric cancer or familial medullary thyroid carcinoma. Multigene panel testing is considered medically appropriate when an individual meets Policy Statement I, except Policy Statements I.A, I.D and I.G.9. The current effective date is April 16, 2026, and the annual update kept the policy intent unchanged.
Blue Cross & Blue Shield of Mississippi · Effective Oct 1, 2025Medium impact
Digital Breast Tomosynthesis
Screening digital breast tomosynthesis (CPT 77063) is covered once per calendar year as an alternative to standard 2D mammography for women beginning at age 35, as part of the Healthy You! Wellness benefit, effective 01/01/2018. Digital breast tomosynthesis may be considered medically necessary as an alternative to standard 2D mammography for further imaging when used for breast cancer diagnostic purposes. Already effective 2025-10-01: ICD-10 diagnosis codes C50.A0, C50.A1 and C50.A2 for malignant neoplasm of breast were added to the code reference.
Aetna · Identified Oct 18, 2026Medium impact
Gonadotropin-Releasing Hormone Analogs and Antagonists (CPB 0501, reviewed 2026-10-14)
Aetna considers gonadotropin-releasing hormone (GnRH) analogs and antagonists medically necessary for commercial plan members only for the specific indications listed for each drug, including leuprolide, goserelin, histrelin, triptorelin, degarelix, cetrorelix and ganirelix, and treats all other indications as experimental, investigational or unproven. Each drug has separate criteria for initial approval and for continuation of therapy, and continuation for prostate cancer requires clinical benefit such as serum testosterone less than 50 ng/dL and no unacceptable toxicity. Precertification is required for the prostate cancer indication, and gender dysphoria treatment for members under 18 must be prescribed by or in consultation with a provider specialized in the care of transgender youth who has collaborated care with a mental health provider.
Aetna · Identified Oct 15, 2026Medium impact
Avelumab (Bavencio) (CPB 0916, reviewed 2026-10-14)
Aetna considers avelumab (Bavencio) medically necessary for commercial plan members with Merkel cell carcinoma, renal cell carcinoma in combination with axitinib, urothelial carcinomas, gestational trophoblastic neoplasia, endometrial carcinoma, thymic carcinoma, extranodal NK/T-cell lymphoma, colorectal adenocarcinoma, and small bowel adenocarcinoma when the criteria for each indication are met. Precertification of avelumab is required for all Aetna participating providers and members in applicable plan designs, and members who have experienced disease progression while on PD-1 or PD-L1 inhibitor therapy are not eligible. Aetna considers avelumab experimental, investigational, or unproven for all other indications, including breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, and pancreatic cancer.
Aetna · Identified Oct 10, 2026Medium impact
Radiofrequency Tumor Ablation (CPB 0492, reviewed 2026-10-05)
Aetna considers radiofrequency ablation (RFA) medically necessary for indications that include colorectal cancer liver metastases, colorectal cancer lung metastases of 5 cm or less where the primary colorectal tumor has been resected for cure (R0 resection), malignant lung masses in persons who are not candidates for surgical intervention, solitary hepatocellular carcinoma of 5 cm or less or multinodular early-stage HCC in members who are ineligible for or decline surgical resection or transplantation, renal cell carcinoma up to 4 cm in high-risk surgical candidates or in persons with renal insufficiency or a solitary kidney, and osteoid osteoma in individuals who remain symptomatic despite NSAIDs. Aetna considers RFA experimental, investigational, or unproven for combined RFA with transarterial chemoembolization for intermediate-stage hepatocellular carcinoma, combined endoluminal RFA and stenting for malignant biliary obstruction or stricture, combined RFA and vertebral cement augmentation for spinal metastases, endoscopic ultrasound-guided RFA for aldosterone-producing adenomas, and all other indications, including curative treatment of primary or metastatic malignant neoplasms in persons able to tolerate surgical resection, biliary obstructions or strictures, renal cysts, renal angiomyolipomas, Brunner's gland hyperplasia, and unresectable localized recurrent thyroid cancers without distant metastases.
Aetna · Identified Oct 8, 2026Medium impact
Docetaxel (CPB 0956, reviewed 2026-10-05)
For commercial medical plans, docetaxel (Beizray, Docivyx, Taxotere, or generic docetaxel) is considered medically necessary for the listed cancer indications, including breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, head and neck cancer, ovarian cancer, small cell lung cancer, and soft tissue sarcoma. Breast cancer requires the disease-status criteria stated in the policy, and continuation of therapy is considered medically necessary when there is no evidence of unacceptable toxicity or disease progression on the current regimen. All other indications are considered experimental, investigational, or unproven.
Aetna · Identified Oct 5, 2026Medium impact
Mammography (CPB 0584, reviewed 2026-09-10)
Annual screening mammography is medically necessary for women aged 40 and older as a preventive service, and for women under 40 who are judged to be at high risk, such as BRCA1 or BRCA2 mutation carriers. Diagnostic mammography is covered for members with signs or symptoms of breast disease or a history of breast cancer, whether or not they have preventive benefits. AI-based mammography, contrast-enhanced mammography for members who do not meet the medical necessity criteria, and screening mammography in men outside the listed indications are considered experimental, investigational or unproven.
Aetna · Identified Oct 3, 2026Medium impact
Liver and Other Neoplasms - Treatment Approaches (CPB 0268, reviewed 2026-09-18)
Aetna considers percutaneous ethanol injection (PEI) medically necessary for hepatocellular carcinoma (HCC) without extra-hepatic spread and for neuroendocrine cancers involving the liver. Chemoembolization is medically necessary for neuroendocrine cancers involving the liver, unresectable primary HCC, liver-only metastasis from uveal melanoma, and pre-operative hepatic artery chemoembolization followed by orthotopic liver transplantation for HCC. Intra-hepatic microspheres (TheraSphere, SIR-Spheres, also known as trans-arterial radio-embolization) are medically necessary for neuroendocrine cancers involving the liver, unresectable primary HCC, unresectable liver tumors from primary colorectal cancer, unresectable and chemo-refractory intra-hepatic cholangiocarcinoma with liver metastases only, and pre-operative use as a bridge to orthotopic liver transplantation for HCC. Intra-hepatic chemotherapy is medically necessary for members with liver metastases from colorectal cancer. Many other uses are listed as experimental, investigational or unproven, including chemoembolization for palliative treatment of liver metastases from non-neuroendocrine primaries, PEI for liver neoplasms when the criteria above are not met, combined electrochemotherapy and immunotherapy for HCC, the TriNav Infusion System, the TheraBionic P1 System, and degradable starch microsphere chemoembolization for HCC.
Aetna · Identified Aug 19, 2026Medium impact
Breast Transillumination, Electrical Impedance Scanning (EIS), and Elastography (CPB 0386, reviewed 2026-05-26)
The policy history lists an original effective date of 02/02/2000 and a last review of 05/26/2026, and no change is described. Aetna considers these procedures experimental, investigational, or unproven because the effectiveness of these approaches has not been established: breast elastography by any method (ultrasound or magnetic resonance); combined shear-wave elastography with ultrasonography for detection of breast cancer; electrical impedance scanning (EIS) of the breast for distinguishing benign from malignant breast lesions; non-elastographic quantitative ultrasound tissue characterization for screening and diagnosis of breast cancer and for all other indications; optical coherence micro-elastography for identifying malignant tissue and lymph node involvement during breast-conserving surgery; opto-acoustic imaging of relative blood oxygen saturation and total hemoglobin for diagnosis of breast cancer; tactile breast imaging by computer-aided tactile sensors (such as BEXA and SureTouch Mobile Pressure Mapping System); and transillumination (optical imaging, light scanning or diaphanography) for detection of breast cancer. Breast transilluminators have not been proven to be an acceptable alternative to conventional mammography.
Aetna · Identified Aug 19, 2026Medium impact
Brachytherapy (CPB 0371, reviewed 2026-05-20)
Aetna considers brachytherapy medically necessary for breast, esophageal, eye tumors, genitourinary cancers other than bladder, gynecologic, head and neck, respiratory and digestive tract, and soft tissue sarcoma indications when the EviCore Healthcare Radiation Therapy Clinical Guidelines criteria are met. It also considers brachytherapy medically necessary for skin cancer where surgical resection and photon or electron beam techniques are contraindicated, and for stenotic obstruction after lung transplantation refractory to other treatments. Brachytherapy for bladder cancer, bone metastases, brain tumors, leukemia, lymphoma, multiple myeloma, pancreatic cancer, keloids, palmoplantar pustulosis, spinal tumors and spinal metastases, and subfoveal choroidal neovascularization secondary to age-related macular degeneration is considered experimental, investigational or unproven, and electronic brachytherapy is considered experimental, investigational or unproven for breast cancer and all other indications.
Aetna · Identified Aug 18, 2026Medium impact
Trastuzumab Products (CPB 0313, reviewed 2026-06-08)
Aetna Clinical Policy Bulletin 0313 sets coverage rules for trastuzumab products for commercial medical plans, including Herceptin and the biosimilars Hercessi, Herzuma, Kanjinti, Ogivri, Ontruzant and Trazimera. Aetna considers these products medically necessary for HER2-positive breast cancer in the adjuvant, neoadjuvant and metastatic settings, for HER2-positive esophageal, gastric, biliary, salivary gland, small bowel, appendiceal and uterine serous cancers, and for HER2-positive, RAS and BRAF wild-type colorectal cancer when the listed criteria are met. Aetna considers all other indications experimental, investigational or unproven, including lung, ovarian, pancreatic, prostate, bladder and melanoma, and considers lapatinib plus trastuzumab and pertuzumab plus trastuzumab for HER2-positive breast cancer experimental, investigational or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Testosterone Enanthate Injection (CPB 1015, reviewed 2026-07-17)
Aetna's clinical policy for intramuscular testosterone enanthate injection (generic Delatestryl) covers it for commercial medical plans when it is medically necessary for hormone-responsive breast cancer in a premenopausal member who has benefited from oophorectomy, delayed puberty, gender dysphoria when prescribed for gender-affirming care, inoperable metastatic breast cancer in a member 1 to 5 years postmenopausal with an incomplete response to other therapy, or primary or hypogonadotropic hypogonadism with at least two confirmed low morning testosterone levels before therapy. Aetna considers age-related or late-onset hypogonadism, female sexual dysfunction or hypoactive sexual desire disorder, heart failure, and improvement of cognitive function in aging men experimental, investigational, or unproven. The brand Delatestryl has been discontinued in the U.S., and an FDA-approved generic equivalent is available.
Aetna · Identified Aug 18, 2026Medium impact
Mammography (CPB 0584, reviewed 2025-09-09)
Aetna considers annual screening mammography medically necessary as a preventive service for women aged 40 and older, and for women under 40 who are judged to be at high risk, such as BRCA1 or BRCA2 mutation carriers and women meeting the other listed risk criteria. Diagnostic mammography is covered for members with signs or symptoms of breast disease or a history of breast cancer, regardless of whether the member has preventive benefits. Digital mammography and digital breast tomosynthesis are acceptable alternatives to film and standard 2D mammography, computer-aided detection is a medically necessary adjunct, and contrast-enhanced mammography is covered only for high-risk members who meet breast MRI criteria but have a documented contraindication, intolerance, or lack of access.
Aetna · Identified Aug 17, 2026Medium impact
Hematopoietic Cell Transplantation for Solid Tumors in Adults (CPB 0811, reviewed 2025-12-03)
Aetna's Clinical Policy Bulletin 0811 considers autologous or allogeneic hematopoietic stem cell transplant, both ablative and non-myeloablative, experimental, investigational, or unproven for the following adult solid tumors: bile duct (cholangiocarcinoma), breast, central nervous system tumors, cervix, colon, esophagus, fallopian tube, gallbladder, kidney, liver, lung, melanoma, nasopharynx, neuroendocrine tumors, pancreas, paranasal sinus, prostate, rectum, soft tissue sarcomas, stomach, thymus, thyroid, tumors of unknown primary origin, and uterus. Aetna considers autologous hematopoietic stem cell transplant medically necessary in young adults with primitive neuroectodermal tumors, medulloblastoma, and Ewing sarcoma family of tumors when criteria are met in CPB 0496.
Aetna · Identified Aug 17, 2026Medium impact
Hematopoietic Cell Transplantation for Breast Cancer (CPB 0507, reviewed 2026-08-06)
Aetna considers autologous, tandem and allogeneic hematopoietic cell transplantation for breast cancer experimental, investigational or unproven, because their effectiveness for this indication has not been established. Aetna will cover these transplants when they are performed in a clinical trial sponsored or authorized by the National Cancer Institute (NCI) or the Federal Food and Drug Administration (FDA), and will continue to cover them off-trial when state mandates or other requirements dictate. Four randomized controlled clinical trials showed that autologous hematopoietic cell transplantation was either similar to or more harmful than standard-dose chemotherapy.
Aetna · Identified Aug 17, 2026Medium impact
Ado-trastuzumab Emtansine (Kadcyla) (CPB 0974, reviewed 2026-01-21)
Aetna covers ado-trastuzumab emtansine (Kadcyla) for commercial medical plans and requires precertification for it. Covered uses include HER2-positive breast cancer in the settings listed in the policy, non-small cell lung cancer with HER2 (ERBB2) mutations when the drug is used as a single agent and the member has not progressed on a HER2 targeted drug such as Enhertu, and recurrent, unresectable or metastatic HER2-positive salivary gland tumors. Aetna considers all other indications experimental, investigational, or unproven, including use together with Herceptin, Tykerb or Perjeta, HER2-negative breast cancer, gastric cancer, colorectal cancer and hepatobiliary cancers.
Aetna · Identified Aug 17, 2026Medium impact
Liver and Other Neoplasms - Treatment Approaches (CPB 0268, reviewed 2026-04-16)
Aetna considers percutaneous ethanol injection, chemoembolization, intra-hepatic chemotherapy and intra-hepatic microspheres (also called TARE) medically necessary for listed liver indications. These include unresectable primary hepatocellular carcinoma (HCC), neuroendocrine tumors involving the liver, liver-only metastasis from uveal melanoma, unresectable liver tumors from colorectal cancer, and pre-operative use before liver transplantation for HCC. The policy considers many other uses experimental, investigational or unproven, including chemoembolization for liver metastases from non-neuroendocrine primaries, combined radiofrequency ablation and percutaneous ethanol injection for HCC, drug-eluting beads for liver metastases from colorectal cancer, the TriNav Infusion System and the TheraBionic P1 System.
Aetna · Identified Aug 16, 2026Medium impact
Margetuximab-cmkb (Margenza) (CPB 0985, reviewed 2026-05-27)
Aetna requires precertification for Margenza (margetuximab-cmkb) for participating providers and members in applicable plan designs. Aetna considers Margenza medically necessary for HER2-positive breast cancer with no response to preoperative systemic therapy, or for HER2-positive recurrent unresectable or metastatic breast cancer, when given with chemotherapy to members who have received two or more prior regimens. Continuation is medically necessary when there is no evidence of unacceptable toxicity or disease progression on the current regimen, and all other indications are considered experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Gonadotropin-Releasing Hormone Analogs and Antagonists (CPB 0501, reviewed 2026-07-10)
Aetna covers gonadotropin-releasing hormone (GnRH) analogs and antagonists under its commercial medical plans for the indications the policy lists, including prostate cancer, breast cancer, ovarian cancer, central precocious puberty, endometriosis, uterine leiomyomata (fibroids), and ovulation induction or assisted reproductive technology. The policy also sets criteria for gender dysphoria treatment, including pubertal suppression in adolescents and gender transition, and for continuation of therapy. Aetna considers all other indications experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Fam-trastuzumab Deruxtecan-nxki (Enhertu) (CPB 0966, reviewed 2026-05-15)
Aetna's policy for fam-trastuzumab deruxtecan-nxki (Enhertu) requires precertification from participating providers and members in applicable plan designs, and it covers the drug for commercial medical plans when the criteria for a listed indication are met. Listed indications include HER2-positive breast cancer, HER2-low and HER2-ultralow breast cancer, HER2-positive biliary tract cancer, HER2-positive esophageal, gastric or gastroesophageal junction adenocarcinoma, HER2-mutant non-small cell lung cancer, and HER2-positive (IHC 3+) solid tumors. Several indications are covered only when Enhertu is used as a single agent, and Aetna considers the drug experimental, investigational or unproven for all other indications.
Aetna · Identified Aug 13, 2026Medium impact
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo) (CPB 0977, reviewed 2026-04-24)
Aetna considers pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo) medically necessary for commercial medical plans in three HER2-positive breast cancer settings: neoadjuvant treatment with chemotherapy for locally advanced, inflammatory, or early-stage disease; adjuvant treatment for locally advanced or early-stage disease; and treatment of recurrent unresectable or metastatic disease or disease with no response to preoperative systemic therapy. All other indications are considered experimental, investigational, or unproven. Phesgo is for subcutaneous use in the thigh only and must not be given intravenously.
Aetna · Identified Aug 13, 2026Medium impact
Dostarlimab-gxly (Jemperli) (CPB 0993, reviewed 2026-01-27)
For commercial medical plan members, Aetna considers dostarlimab-gxly (Jemperli) medically necessary under its initial approval criteria for several mismatch repair deficient or microsatellite instability-high cancers, including endometrial, ampullary, breast, colorectal, esophageal, gastric, ovarian, pancreatic, small bowel and anal cancers. It also considers Jemperli in combination with pemetrexed and platinum chemotherapy for first-line metastatic nonsquamous non-small cell lung cancer without genomic aberrations. Members are not eligible when they have experienced disease progression while on PD-1 or PD-L1 inhibitor therapy, and all other indications are considered experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Datopotamab Deruxtecan-dlnk (Datroway) (CPB 1078, reviewed 2026-05-15)
For commercial medical plans, Aetna considers datopotamab deruxtecan-dlnk (Datroway) medically necessary for unresectable or metastatic HR-positive, HER2-negative breast cancer after endocrine-based therapy and chemotherapy for unresectable or metastatic disease, when the member is not a candidate for fam-trastuzumab deruxtecan-nxki (Enhertu). It also considers Datroway medically necessary as single-agent first-line treatment of recurrent, unresectable or metastatic triple negative breast cancer that is ER, PR and HER2 negative with PD-L1 CPS less than 10 and no germline BRCA 1/2 pathogenic variants, and as single-agent subsequent treatment of EGFR mutation-positive recurrent, advanced, or metastatic non-small cell lung cancer. Aetna considers all other indications experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Dinutuximab (Unituxin) (CPB 0895, reviewed 2025-10-23)
Aetna considers dinutuximab (Unituxin) medically necessary for high-risk neuroblastoma in members less than 21 years of age, in combination with sargramostim, aldesleukin and 13-cis-retinoic acid (isotretinoin), once the member has achieved at least a partial response to prior first-line multiagent, multimodality therapy. The policy also covers chemoimmunotherapy with temozolomide, irinotecan and sargramostim in specified high-risk disease settings, and continuation therapy for up to a maximum of 5 cycles. Aetna considers dinutuximab experimental, investigational or unproven for all other indications, including Ewing sarcoma, Ewing-like sarcoma, glioblastoma multiforme, lung cancer, osteosarcoma and triple-negative breast cancer.
Aetna · Identified Aug 12, 2026Medium impact
Optical Coherence Tomography and Microelastography for Solid Tumors and Other Selected Indications (CPB 0886, reviewed 2026-03-03)
Aetna considers optical coherence tomography and microelastography experimental, investigational, or unproven for the listed intra-operative uses because their effectiveness has not been established. These uses include assessment of lymph nodes or tumor margins in breast conserving surgery, differentiation of pancreatic neoplastic lesions, differentiation of normal and diseased thyroid and parathyroid tissues, and solid tumor surgery including optical biopsy of lymph nodes and real-time determination of surgical margins. The policy lists CPT codes and ICD-10 codes as not covered for the indications it names.
Aetna · Identified Nov 4, 2026Low impact
Microwave Thermotherapy (CPB 0682, reviewed 2026-10-26)
Aetna's Microwave Thermotherapy policy (CPB 0682) was reviewed on 2026-10-26, and the source does not state what changed or give a new effective date. It covers microwave thermotherapy as medically necessary only for T1 renal lesions, medically inoperable non-small cell lung cancer lesions under 3 cm, and hepatocellular carcinoma tumors of 3 cm or less, and it lists many other uses (such as breast, pancreatic, bladder, and chronic pain indications) as experimental, investigational or unproven.

Watch C50.929

Get one email when a payer policy names C50.929, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code C50.929?

There are 27 tracked policy changes affecting code C50.929, including updates from Healthfirst, Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code C50.929?

Payers that have issued tracked updates for code C50.929 include: Healthfirst, Excellus BlueCross BlueShield, Blue Cross & Blue Shield of Mississippi, Aetna.

How do I get notified when code C50.929 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code C50.929. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code C50.929?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

NYS Medicaid Breast Cancer Selective Program Reimbursement Policy

Germline Genetic Testing for Hereditary Cancers 2.02.60

Digital Breast Tomosynthesis

Gonadotropin-Releasing Hormone Analogs and Antagonists (CPB 0501, reviewed 2026-10-14)

Avelumab (Bavencio) (CPB 0916, reviewed 2026-10-14)

Radiofrequency Tumor Ablation (CPB 0492, reviewed 2026-10-05)

Docetaxel (CPB 0956, reviewed 2026-10-05)

Mammography (CPB 0584, reviewed 2026-09-10)

Liver and Other Neoplasms - Treatment Approaches (CPB 0268, reviewed 2026-09-18)

Breast Transillumination, Electrical Impedance Scanning (EIS), and Elastography (CPB 0386, reviewed 2026-05-26)

Brachytherapy (CPB 0371, reviewed 2026-05-20)

Trastuzumab Products (CPB 0313, reviewed 2026-06-08)

Testosterone Enanthate Injection (CPB 1015, reviewed 2026-07-17)

Mammography (CPB 0584, reviewed 2025-09-09)

Hematopoietic Cell Transplantation for Solid Tumors in Adults (CPB 0811, reviewed 2025-12-03)

Hematopoietic Cell Transplantation for Breast Cancer (CPB 0507, reviewed 2026-08-06)

Ado-trastuzumab Emtansine (Kadcyla) (CPB 0974, reviewed 2026-01-21)

Liver and Other Neoplasms - Treatment Approaches (CPB 0268, reviewed 2026-04-16)

Margetuximab-cmkb (Margenza) (CPB 0985, reviewed 2026-05-27)

Gonadotropin-Releasing Hormone Analogs and Antagonists (CPB 0501, reviewed 2026-07-10)

Fam-trastuzumab Deruxtecan-nxki (Enhertu) (CPB 0966, reviewed 2026-05-15)

Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo) (CPB 0977, reviewed 2026-04-24)

Dostarlimab-gxly (Jemperli) (CPB 0993, reviewed 2026-01-27)

Datopotamab Deruxtecan-dlnk (Datroway) (CPB 1078, reviewed 2026-05-15)

Dinutuximab (Unituxin) (CPB 0895, reviewed 2025-10-23)

Optical Coherence Tomography and Microelastography for Solid Tumors and Other Selected Indications (CPB 0886, reviewed 2026-03-03)

Microwave Thermotherapy (CPB 0682, reviewed 2026-10-26)

What insurance policy changes affect code C50.929?

Which payers have updated policy for code C50.929?

How do I get notified when code C50.929 policy changes?

Why do payers change policies for code C50.929?